Advertisement
Advertisement

SUPN

SUPN logo

Supernus Pharmaceuticals, Inc.

48.81
USD
Sponsored
+0.65
+1.35%
Feb 02, 16:00 UTC -5
Closed
exchange

After-Market

48.80

-0.01
-0.01%

SUPN Earnings Reports

Positive Surprise Ratio

SUPN beat 29 of 40 last estimates.

73%

Next Report

Date of Next Report
Feb 23, 2026
Estimate for Q4 25 (Revenue/ EPS)
$198.46M
/
$0.44
Implied change from Q3 25 (Revenue/ EPS)
+3.31%
/
-56.44%
Implied change from Q4 24 (Revenue/ EPS)
+13.95%
/
-41.33%

Supernus Pharmaceuticals, Inc. earnings per share and revenue

On Nov 04, 2025, SUPN reported earnings of 1.01 USD per share (EPS) for Q3 25, beating the estimate of 0.60 USD, resulting in a 67.83% surprise. Revenue reached 192.10 million, compared to an expected 182.47 million, with a 5.28% difference. The market reacted with a -17.35% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 8 analysts forecast an EPS of 0.44 USD, with revenue projected to reach 198.46 million USD, implying an decrease of -56.44% EPS, and increase of 3.31% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Teva Pharmaceutical Industries Limited - ADR
Report Date
Jan 28, 2026 For Q4 25
Estimate
$0.69
Actual
$0.96
Surprise
+38.55%
logo
Dr. Reddy's Laboratories Limited - ADR
Report Date
Jan 21, 2026 For Q3 26
Estimate
$13.86
Actual
$14.65
Surprise
+5.66%
FAQ
For Q3 2025, Supernus Pharmaceuticals, Inc. reported EPS of $1.01, beating estimates by 67.83%, and revenue of $192.10M, 5.28% above expectations.
The stock price moved down -17.35%, changed from $57.00 before the earnings release to $47.11 the day after.
The next earning report is scheduled for Feb 23, 2026.
Based on 8 analysts, Supernus Pharmaceuticals, Inc. is expected to report EPS of $0.44 and revenue of $198.46M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement